Clinicopathological characteristics | OS survival | |||
---|---|---|---|---|
N | Hazard ratio | P-value | ||
Gender: | Female | 133 | 1.56 (0.95–2.55) | 0.076 |
Male | 366 | 1.43 (1.01–2.03) | 0.041 | |
Race: | White | 426 | 0.35 (1.01–1.82) | 0.044 |
black/African American | 47 | 3.4 (1.3–8.91) | 0.0084 | |
1 | 25 | 7.29 (0.76–70.09) | 0.044 | |
Stage | 2 | 69 | 0.45 (0.2–1) | 0.043 |
3 | 78 | 1.55 (0.68–3.55) | 0.29 | |
4 | 259 | 1.75 (1.21–2.53) | 0.0027 | |
1 | 61 | 1.94 (0.8–4.7) | 0.14 | |
Grade: | 2 | 298 | 1.29 (0.91–1.82) | 0.15 |
3 | 119 | 2.25 (1.29–3.92) | 0.0033 | |
4 | 7 | |||
high | 251 | 1.34 (0.91–1.98) | 0.14 | |
Mutation burden: | low | 243 | 1.95 (1.29–2.97) | 0.0014 |
enriched | 243 | 1.7 (1.11–2.6) | 0.013 | |
Basophils: | decreased | 254 | 1.22 (0.83–1.79) | 0.3 |
enriched | 238 | 2.07 (1.31–3.28) | 0.0015 | |
B-cells: | decreased | 259 | 1.16 (0.77–1.73) | 0.48 |
enriched | 316 | 1.66 (1.16–2.37) | 0.0048 | |
CD4+ memory T-cells: | decreased | 181 | 1.3 (0.84–2.01) | 0.24 |
enriched | 305 | 1.55 (1.05–2.27) | 0.025 | |
CD8+ T-cells: | decreased | 192 | 1.62 (1.04–2.51) | 0.03 |
enriched | 215 | 1.55 (1.05–2.27) | 0.025 | |
Eosinophils: | decreased | 282 | 1.53 (1.07–2.19) | 0.02 |
enriched | 205 | 1.49 (0.91–2.38) | 0.12 | |
Macrophages: | decreased | 292 | 1.34 (0.93–1.94) | 0.12 |
enriched | 313 | 1.62 (1.15–2.27) | 0.0053 | |
Mesenchymal stem cells: | decreased | 184 | 1.33 (0.85–2.07) | 0.21 |
enriched | 129 | 1.54 (0.94–2.52) | 0.082 | |
Natural killer T-cells: | decreased | 368 | 1.36 (0.97–1.9) | 0.077 |
enriched | 322 | 1.43 (1.01–2.01) | 0.04 | |
Regulatory T-cells: | decreased | 175 | 1.54 (0.95–2.48) | 0.074 |
enriched | 381 | 1.53 (1.11–2.11) | 0.0082 | |
Type 1 T-helper cells: | decreased | 116 | 1.38 (0.8–2.39) | 0.24 |
enriched | 473 | 1.39 (1.04–1.85) | 0.024 | |
Type 2 T-helper cells: | decreased | 24 | 4.84 (0.8–29.1) | 0.057 |